Effective LHRH agonist therapy for advanced prostatic carcinoma in a convenient, acceptable form.

* As effective as orchidectomy
Reduces and maintains testosterone at castrate levels with a single monthly s.c. injection

* Improved quality of life
Good objective response, enhanced performance status, improved general well being

* More acceptable than goserelin for patients
The latest in depot technology – a very fine suspension which may be given through a 23 gauge needle

* Well tolerated and free from major side effects

**PROSTAP* SR**
A depot solution in prostate cancer

Prostap SR Abbreviated Prescribing Information
Before prescribing Prostap SR, please refer to full data sheet.

**Indications** Advanced prostatic cancer. **Dosages** 3.75mg as a subcutaneous injection every 4 weeks. Do not discontinue when remission or improvement occurs.

**Vary injection site. Elderly, as for adults. Contraindications** No known contraindications. **Warnings** A transient rise in levels of testosterone, dihydro-testosterone and acid phosphatase may occur initially. This may be associated with tumour flare, sometimes manifesting as systemic or neurological symptoms. These symptoms usually subside on continuation of therapy. Patients at risk of ureteric obstructions or spinal cord compression should be closely supervised in the first few weeks of treatment. These patients should be considered for prophylactic treatment with anti-androgens. Should urological/neurological complications occur, these should be specifically treated. **Precautions** Patients with urinary obstruction or metastatic vertebral lesions should begin Prostap under close supervision for the first few weeks of treatment. **Side-effects** If tumour flare occurs, symptoms or signs due to disease, e.g bone pain and/or urinary obstruction may also occur. Impotence, decreased libido, hot flushes and sweating. Occasionally, peripheral oedema, fatigue, nausea and injection site irritation. **Legal Category** POM. **Presentation** Vials containing 3.75mg leuprolin acetate as microcapillary powder. Prefilled syringes containing 3ml vehicle.

**Basic NHS Price:** £125.40. **Product Licence Numbers:** Prostap SR Powder 3.75mg PL 0095/0218. Sterile Vehicle PL0095/0220.


Further information is available on request. Lederle Laboratories, Fareham Road, Gosport, Hants, PO13 0AS. Tel: 0239 224000

Prostap is a trademark.
Hormones, Cancer and the Reproductive System
Simpson Symposium No.4
9–13 September 1991

These Symposia seek to provide research fellows, young clinicians and health professionals from the UK, Europe, the developing world and elsewhere with the latest scientific developments as they relate to clinical practice. The staff of the Centre and guest contributors plan to provide a stimulating view of current research and take a forward look to its application. The programme for 1991 will include the biology of cell growth, malignant transformation, hormone dependence, screening and prevention. The mornings will be devoted to seminars by the speakers listed below, the afternoons to practical demonstrations and poster displays including those contributed by registrants, each day terminating with a round table discussion.

**Speakers will include**

- **Professor Sir Patrick Forrest (Edinburgh)**
- **Dr Peter Boyle (Lyon)**
- **Professor Stuart Campbell (London)**
- **Dr Lionel Crawford (Cambridge)**
- **Professor N E Day (Cambridge)**
- **Dr Robert B Dickson (Washington)**
- **Dr Colby Eaton (Cardiff)**
- **Professor Barry A Gusterson (London)**
- **Dr Roger J B King (London)**
- **Professor Edward Milgrom (Paris)**

---

**Course Organisers**

* Professor D T Baird * Professor A A Calder * Professor D W Lincoln * Dr N B Loudon * Dr G E Smart

---

**Course fee**

£200 (includes Symposium Dinner, lunches and ceilidh but not accommodation)

---

**Further information and application form from**

Simpson Symposium Secretariat, Centre for Reproductive Biology, 31st Chalmers Street, Edinburgh EH3 9EW. Tel: 031 229 2575 Fax: 031 228 5571